IN2012DN00977A - - Google Patents

Info

Publication number
IN2012DN00977A
IN2012DN00977A IN977DEN2012A IN2012DN00977A IN 2012DN00977 A IN2012DN00977 A IN 2012DN00977A IN 977DEN2012 A IN977DEN2012 A IN 977DEN2012A IN 2012DN00977 A IN2012DN00977 A IN 2012DN00977A
Authority
IN
India
Prior art keywords
diabetes
type
postprandial hyperglycemia
spot treatment
dosage
Prior art date
Application number
Inventor
Philipee Perovitch
Marc Maury
Jean-Pierre Dumonteix
Original Assignee
Perovitch Philippe
Marc Maury
Dumonteix Jean Pierre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perovitch Philippe, Marc Maury, Dumonteix Jean Pierre filed Critical Perovitch Philippe
Publication of IN2012DN00977A publication Critical patent/IN2012DN00977A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 3 0% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. The invention also pertains to a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes.
IN977DEN2012 2009-07-10 2010-07-07 IN2012DN00977A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0954819A FR2947729B1 (en) 2009-07-10 2009-07-10 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TYPE II DIABETES BY ORAL TRANS-MUCOSAL METHOD
PCT/FR2010/051426 WO2011004117A1 (en) 2009-07-10 2010-07-07 Method and pharmaceutical compositions for trans-buccal mucosa treatment of postprandial hyperglycaemia in type ii diabetes

Publications (1)

Publication Number Publication Date
IN2012DN00977A true IN2012DN00977A (en) 2015-04-10

Family

ID=41571558

Family Applications (1)

Application Number Title Priority Date Filing Date
IN977DEN2012 IN2012DN00977A (en) 2009-07-10 2010-07-07

Country Status (10)

Country Link
US (1) US9161910B2 (en)
EP (1) EP2451436A1 (en)
JP (1) JP2012532852A (en)
CN (1) CN102481254A (en)
BR (1) BR112012000596A2 (en)
FR (1) FR2947729B1 (en)
IN (1) IN2012DN00977A (en)
MX (1) MX337606B (en)
RU (1) RU2543635C2 (en)
WO (1) WO2011004117A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940116B1 (en) * 2008-12-22 2012-07-06 Philippe Perovitch FORMULATION FOR THE ADMINISTRATION OF HYPOLIPEMIC BY ORAL TRANS-MUCOSAL
FR3000896B1 (en) * 2013-01-14 2016-08-26 Philippe Perovitch GALENIC FORM FOR ADMINISTRATION OF ACTIVE INGREDIENT (S) FOR ACCELERATED INDUCTION OF SLEEP AND / OR TREATMENT OF SLEEP DISORDERS
FR3031668A1 (en) 2015-01-20 2016-07-22 Philippe Perovitch DEVICE FOR DELIVERY OF ACTIVE PRINCIPLE BY PERMUCOSAL MOUTH.
FR3053244A1 (en) 2016-07-01 2018-01-05 Philippe Perovitch DEVICE FOR DELIVERY OF AT LEAST ONE ACTIVE PRINCIPLE BY PERMUCOSAL MOUTH.
CN107669683B (en) * 2017-09-30 2020-07-03 杭州华东医药集团新药研究院有限公司 Pharmaceutical composition containing sitagliptin and metformin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2071779C1 (en) * 1993-05-12 1997-01-20 Хабаровский химико-фармацевтический завод Method of preparing pantocrin for injection
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
SE528866C2 (en) * 2005-07-01 2007-02-27 Volvo Lastvagnar Ab Apparatus for controlling the height of a load or load carrier behind the cab of a truck
NZ591609A (en) * 2005-08-30 2012-10-26 Abbott Lab Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
DE102006027790A1 (en) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Type 2 diabetes combination wafers
EP2068831A4 (en) * 2006-07-28 2010-07-21 Novadel Pharma Inc Anti-migraine oral spray formulations and methods
FR2906140B1 (en) * 2006-09-22 2008-12-05 Philippe Perovitch GALENIC FORM FOR TRANSMUCOSUS ADMINISTRATION OF ACTIVE INGREDIENTS

Also Published As

Publication number Publication date
FR2947729B1 (en) 2012-01-20
BR112012000596A2 (en) 2016-02-10
CN102481254A (en) 2012-05-30
WO2011004117A1 (en) 2011-01-13
MX2012000466A (en) 2012-04-19
MX337606B (en) 2016-03-10
US20120190618A1 (en) 2012-07-26
RU2543635C2 (en) 2015-03-10
JP2012532852A (en) 2012-12-20
US9161910B2 (en) 2015-10-20
RU2012104639A (en) 2013-08-20
EP2451436A1 (en) 2012-05-16
FR2947729A1 (en) 2011-01-14

Similar Documents

Publication Publication Date Title
MX2011010347A (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof.
PE20130511A1 (en) LONG-ACTING INSULIN FORMULATIONS
EA201491934A1 (en) GLUCAGON-LIKE PEPTIDE-2 ANALOGES (GLP-2)
EA201491060A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
CY1119582T1 (en) HYDRAULIC INSULIN PREPARATIONS CONTAINING Methionine
NO20084919L (en) oxadiazolidinedione
BR112015013809A2 (en) exendin-4 derivatives as glp1 / gip double agonists or glp1 / gip / lucagon trigonals, their use and pharmaceutical composition
CL2008000198A1 (en) COMPOUNDS DERIVED FROM AZACICLOALCANOS, INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF SICK DISEASES AS TYPE 2 DIABETES, LIPID DISORDER, OBESITY AND ATEROSCLEROSIS.
EA201490521A1 (en) OPTIONS OF FIBROBLAST GROWTH FACTOR 21
MX2012006744A (en) Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases.
CL2009001340A1 (en) Composed of pegylated insulin lispro or a salt thereof comprising a chain a of sec no: 1, a chain b of sec no: 3 and the peg is of a weight between 20 to 40 kda; use of said compound to treat hypoglycemia or diabetes; pharmaceutical composition comprising said compound; and process for making said compound.
CY1117603T1 (en) LIXISENATIDE AS AN ADDITION TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES
UA96441C2 (en) Pharmaceutical composition comprosing thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
MX2009011359A (en) Pyrimidinone derivatives and methods of use thereof.
EA201290078A1 (en) HETEROCYCLIC COMPOUNDS TO INHIBIT PASK
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
EA201200968A1 (en) USE OF TRANS-CLOMIPHENE FOR THE PREVENTION OR TREATMENT OF DIABETES TYPE 2 IN MEN
MX2011006315A (en) Glucagon analogues.
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
BR112013029256A2 (en) "Pharmaceutical combinations for use in the treatment of patients with type 2 diabetes, treatment method, and uses of lixisenatide and metformin."
CL2007001886A1 (en) Compounds derived from piperidine or pyrrolidine ureas; preparation procedure; pharmaceutical composition; and its use as modulators of the activity of 11ß-hydroxysteroid dehydrogenase type 1 (11ßhsd1) to treat obesity, diabetes, insulin resistance, cushing syndrome and hypertension, among others.
MX2012006734A (en) Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases.
LT2013018A (en) Pharmaceutical composition for treating diabetes and metabolic disorders
MX360554B (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2.